Abstract:Protein kinases play pivotal roles in various biological functions, influencing cell differentiation, promoting survival, and regulating the cell cycle. The disruption of protein kinase activity is intricately linked to pathways in tumor development. This manuscript explores the transformative impact of protein kinase inhibitors on cancer therapy, particularly their efficacy in cases driven by targeted mutations. Focusing on key tyrosine kinase inhibitors (TKIs) like Bcr-Abl, Epidermal Growth Factor Receptor (EGFR), and Vascular Endothelial Growth Factor Receptor (VEGFR), it targets critical kinase families in cancer progression. Clinical trial details of these TKIs offer insights into their therapeutic potentials. Learning from FDA-approved kinase inhibitors, the review dissects trends in kinase drug development since imatinib's paradigm-shifting approval in 2001. TKIs have evolved into pivotal drugs, extending beyond oncology. Ongoing clinical trials explore novel kinase targets, revealing the vast potential within the human kinome. The manuscript provides a detailed analysis of advancements until 2022, discussing the roles of specific oncogenic protein kinases in cancer development and carcinogenesis. Our exploration on PubMed for relevant and significant TKIs undergoing pre-FDA approval phase III clinical trials enriches the discussion with valuable findings. While kinase inhibitors exhibit lower toxicity than traditional chemotherapy in cancer treatment, challenges like resistance and side effects emphasize the necessity of understanding resistance mechanisms, prompting the development of novel inhibitors like osimertinib targeting specific mutant proteins. The review advocates thorough research on effective combination therapies, highlighting the future development of more selective RTKIs to optimize patient-specific cancer treatment and reduce adverse events.

The Role of Organic Cation Transporters in the Pharmacokinetics, Pharmacodynamics and Drug-Drug Interactions of Tyrosine Kinase Inhibitors

Interaction of tyrosine kinase inhibitors with the MDR- related ABC transporter proteins.

Tyrosine Kinase Inhibitors-Induced Arrhythmias: From Molecular Mechanisms, Pharmacokinetics to Therapeutic Strategies

Mechanism and Treatment of Diarrhea Associated with Tyrosine Kinase Inhibitors

Insight to Pharmacokinetics of TKIs: Optimizing Practical Guidelines for Individualized Therapy

Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective

Targeting oncogenic kinases: Insights on FDA approved tyrosine kinase inhibitors

Clinical pharmacokinetics and drug–drug interactions of tyrosine-kinase inhibitors in chronic myeloid leukemia: A clinical perspective

Exploring receptor tyrosine kinases-inhibitors in Cancer treatments

Recent advances in metabolism and toxicity of tyrosine kinase inhibitors

Kinase Inhibitors and Kinase-Targeted Cancer Therapies: Recent Advances and Future Perspectives

Metabolic activation of tyrosine kinase inhibitors: recent advance and further clinical practice

Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management

Mechanisms of Acquired Resistance to Tyrosine Kinase Inhibitors

Advances in studies of tyrosine kinase inhibitors and their acquired resistance

Tyrosine kinase inhibitors and atherosclerosis: A close but complicated relationship

Nanoformulations of small molecule protein tyrosine kinases inhibitors potentiate targeted cancer therapy

In Vitro and In Vivo Inhibition of MATE1 by Tyrosine Kinase Inhibitors

Systematic Evaluation of Tyrosine Kinase Inhibitors as OATP1B1 Substrates Using a Competitive Counterflow Screen

The Progress of Tyrosine kinase Inhibitors in Cancer Therapy

Playing Hide-and-Seek with Tyrosine Kinase Inhibitors: Can We Overcome Administration Challenges?